Immunogenicity and Safety Study of 1 and 2 Doses of GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Pneumococcal Vaccine Prevenar 13

Trial Profile

Immunogenicity and Safety Study of 1 and 2 Doses of GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Pneumococcal Vaccine Prevenar 13

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Meningococcal infections; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms MENACWY-TT-104
  • Sponsors GlaxoSmithKline; Pfizer
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
    • 21 Mar 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
    • 12 Oct 2014 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top